Company: PBH
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001295947-25-000029
Chunk: 12

Company: Prestige Consumer Healthcare Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Item 2
Chunk 12
---
112 2.0 4,083 1.5 1,029 25.2 Gastrointestinal14,088 5.7 13,728 5.1 360 2.6 Eye & Ear Care4,527 1.8 4,811 1.8 (284)(5.9)Dermatologicals2,257 0.9 1,752 0.7 505 28.8 Oral Care3,548 1.4 3,100 1.2 448 14.5 Other OTC92 — 334 0.1 (242)(72.5)Total International OTC Healthcare36,952 14.8 34,826 13.0 2,126 6.1 Total Consolidated$249,530 100.0 $267,142 100.0 $(17,612)(6.6)

Total revenues for the three months ended June 30, 2025 were $249.5 million, a decrease of $17.6 million, or 6.6%, versus the three months ended June 30, 2024.    

North American OTC Healthcare Segment

Revenues for the North American OTC Healthcare segment decreased $19.7 million, or 8.5%, during the three months ended June 30, 2025 versus the three months ended June 30, 2024.  The $19.7 million decrease was primarily attributable to a decrease in sales in the Eye & Ear Care and Dermatologicals categories.  The decrease in the Eye & Ear Care category was primarily due to limited ability to supply demand for Clear Eyes.

International OTC Healthcare Segment

Revenues for the International OTC Healthcare segment increased $2.1 million, or 6.1%, during the three months ended June 30, 2025 versus the three months ended June 30, 2024. The $2.1 million increase was mainly attributable to increases in sales in the Women's Health and Dermatologicals categories.

21

Gross Profit

The following table presents our gross profit and gross profit as a percentage of total segment revenues, by segment for each of the periods presented.

Three Months Ended June 30,(In thousands)Increase (Decrease)Gross Profit 2025%2024%Amount%North American OTC Healthcare $120,400 56